Ifosfamide, carboplatin, and etoposide for neuroblastoma
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.27783/fullpdf
Reference41 articles.
1. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high risk neuroblastoma: A Children's Oncology Group study;Park;J Clin Oncol.,2011
2. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study;Saylors;J Clin Oncol.,2001
3. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma;Kushner;J Clin Oncol.,2006
4. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study;Wagner;J Clin Oncol.,2009
5. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma;Garaventa;Cancer.,2003
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma;Scientific Reports;2023-11-14
2. Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma;Frontiers in Oncology;2023-02-03
3. Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience;Frontiers in Oncology;2022-12-23
4. MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment;BMC Cancer;2022-06-17
5. Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma;Cancer Medicine;2022-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3